<DOC>
	<DOCNO>NCT01959399</DOCNO>
	<brief_summary>The purpose study assess effect multiple-doses ASP015K pharmacokinetics rosuvastatin healthy adult male female subject .</brief_summary>
	<brief_title>Drug-Drug Interaction Study Evaluating Effects ASP015K Rosuvastatin</brief_title>
	<detailed_description />
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Subject Body Mass Index ( BMI ) range 18.532.0 kg/m2 , inclusive , must weigh least 50 kg screening . Asian subject must first generation Japanese born Japan parent four grandparent Japanese descent reside outside Japan 5 year less , first generation Chinese born China parent four grandparent Chinese descent reside outside China 5 year less , first generation Korean born Korea parent four grandparent Korean descent reside outside Korea 5 year less . NonAsian subject selfreported White , Black African American , Hispanic Latino . Female subject must nonchildbearing potential ( i.e. , postmenopausal [ define least 1 year without menses ] prior screen document surgically sterile status post hysterectomy [ least 1 month prior screen ] ) . Female subject must negative pregnancy test screen day 1 . Female subject must donate ovum start screen throughout study period , 90 day final study drug administration . Male subject female spouse/partner childbearing potential must use highly effective contraception consist two form birth control ( one must barrier method ) start screen continue throughout study period 90 day final study drug administration . Male subject must donate sperm screen throughout study period 90 day final study drug administration . Subject agree participate another investigational study treatment . Subject must capable swallow multiple tablet . Female subject pregnant within 6 month screen assessment breast feeding within 3 month screen . Subject know suspected hypersensitivity rosuvastatin , ASP015K , component formulation use . Subject previous intolerance adverse reaction statin therapy . Subject clinically significant history allergic condition ( include drug allergy , asthma , eczema , anaphylactic reaction , exclude untreated , asymptomatic , seasonal allergy time dose ) . Subject history evidence clinically significant cardiovascular , gastro intestinal , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary neurologic , dermatologic , psychiatric , renal , and/or major disease malignancy , judge Investigator designee . Subject has/had febrile illness symptomatic , viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 1 week prior day 1 . Subject mean pulse &lt; 40 &gt; 90 beat per minute ( bpm ) ; mean systolic blood pressure ( SBP ) &gt; 140 mmHg ; mean diastolic blood pressure ( DBP ) &gt; 90 mmHg ( measurement take triplicate subject rest sit position least 5 minute screen day 1 . Subject use prescribe nonprescribed drug ( include vitamin , natural herbal remedy , e.g . St. John 's Wort ) 2 week prior study drug administration , exception hormone replacement therapy ( HRT ) intermittent acetaminophen ( maximum 2 g/day ) . Subject smoke used tobaccocontaining product nicotine nicotine containing product past 6 month prior screen . Subject history consume 14 unit alcoholic beverage per week within 6 month prior screen history alcoholism drug/chemical/substance abuse within past 2 year prior screen ( Note : one unit = 12 ounce beer , 4 ounce wine 1 ounce spirit ) . Subject positive test alcohol , drug abuse , cotinine screen day 1 . Subject use inducer liver metabolism ( e.g . barbiturate , rifampin ) 3 month prior day 1 . Subject significant blood loss , donate one unit ( 450 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day prior clinic checkin day 1 . Subject positive serology test hepatitis B surface antigen ( HBsAg ) ( total ) , anti hepatitis A virus ( Ig M ) , antihepatitis C virus , antihepatitis B core , anti HIV type 1 type 2 screening . Subject participate interventional clinical study treat investigational drug within 30 day 5 halflives drug , whichever longer , prior screen . Subject positive tuberculosis ( TB ) skin test , Quantiferon Gold test TSPOTÂ® test screening . Subject receive vaccine within 60 day prior study drug administration . Subject major gastrointestinal surgery medical condition may inhibit absorption and/or metabolism study drug . Subject anticipate inability abstain xanthine ( e.g. , caffeine ) , grapefruit , Seville blood orange ( include marmalade ) , star fruit , product contain item 72 hour prior day 1 throughout duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>ASP015K</keyword>
	<keyword>healthy subject</keyword>
</DOC>